Matches in Nanopublications for { ?s ?p "[To test the biologic activity of 13-cis retinoic acid (13-CRA) in patients with myelodysplastic states (MDS), we administered 13-CRA orally (2.5 mg/kg/d initially, escalated to 4 mg/kg/d) for 8 weeks to 15 consecutive patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 3 of
3
with 100 items per page.
- NP647702.RArYefwocjUlGfhwPRwyXSCiwWg1vf2J-Hgi67pcBmTzw130_assertion description "[To test the biologic activity of 13-cis retinoic acid (13-CRA) in patients with myelodysplastic states (MDS), we administered 13-CRA orally (2.5 mg/kg/d initially, escalated to 4 mg/kg/d) for 8 weeks to 15 consecutive patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP647702.RArYefwocjUlGfhwPRwyXSCiwWg1vf2J-Hgi67pcBmTzw130_provenance.
- NP732928.RAZz8s8mYNcsBdF6AR-4ksbMbh5TNjfnPsdRMLl7V8ehk130_assertion description "[To test the biologic activity of 13-cis retinoic acid (13-CRA) in patients with myelodysplastic states (MDS), we administered 13-CRA orally (2.5 mg/kg/d initially, escalated to 4 mg/kg/d) for 8 weeks to 15 consecutive patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP732928.RAZz8s8mYNcsBdF6AR-4ksbMbh5TNjfnPsdRMLl7V8ehk130_provenance.
- NP796171.RA7TN2aeLdeBrlK6S5S_ky-NKZh3eH226Ihe9a8DSKXR8130_assertion description "[To test the biologic activity of 13-cis retinoic acid (13-CRA) in patients with myelodysplastic states (MDS), we administered 13-CRA orally (2.5 mg/kg/d initially, escalated to 4 mg/kg/d) for 8 weeks to 15 consecutive patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP796171.RA7TN2aeLdeBrlK6S5S_ky-NKZh3eH226Ihe9a8DSKXR8130_provenance.